SEC Form 4 · accession 0002042910-26-000003
Aura Biosciences, Inc. · AURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amy Elazzouzi
Officer — SVP, Finance & PAO
Period of report
Sep 1, 2026
Accepted (ET)
Sep 1, 2026 · 5:23 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001501796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 1, 2026 | A | 23,540 | $0.00 | A | 143,600 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $7.43 | Sep 1, 2026 | A | 46,460 | A | — | Sep 1, 2036 | Common Stock | 46,460 | 46,460 | D |
Explanation of responses
- F1The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027.
- F2The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026.